Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Yun Zhong Zhu"'
Autor:
Hai Ying Wu, Shi Ying Yu, Chang Ping Wu, Xiao A. Hu, He Huang, Ying Liang, Cai Cun Zhou, Jian Ping Xiong, Qing Xiang Shao, Zhong Zhen Guan, Shunchang Jiao, Yang Zhang, Xu Qing Yang, Ke Jun Liu, Jie Wang, Yun Zhong Zhu, Shaobin Wang, Jin Peng, Yu Xian Bai, Shi Xiu Wu, Mengzhao Wang, Ji Feng
Publikováno v:
Archives of Medical Science : AMS
Introduction The aim of this study was to compare the efficacy and toxicity of dicycloplatin plus paclitaxel with those of carboplatin plus paclitaxel as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC). Material and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d70dfbc5484fbfe93df5d06b737d06b
http://europepmc.org/articles/PMC4175772
http://europepmc.org/articles/PMC4175772
Autor:
Meilin Liao, Teena M. West, Huan-ying Wan, Belinda J. Hall, Long-yun Li, Li Wang, Shiying Yu, Yun-zhong Zhu
Publikováno v:
Chinese Medical Journal. 121:892-897
Background Gemcitabine plus cisplatin is a standard treatment for stages IIIB and IV nonsmall cell lung cancer (NSCLC). This randomized phase II study evaluated a 3-week versus a 4-week schedule of gemcitabine-cisplatin as first line treatment for Ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b63a42b3b714322d8ec8a1a3e1984d24
https://doi.org/10.1097/00029330-200805020-00006
https://doi.org/10.1097/00029330-200805020-00006
Autor:
Wen-Xia Huang, Yun-zhong Zhu, Huaqing Wang, Wen-hua Zhao, Zhenjiu Wang, Liyan Xu, Qiang Chen, Mei-zhen Zhou, Shuanqi Liu, Rongsheng Zheng, Shun-Chang Jiao, Yetao Gao, Jingpo Zhao, Yang Zhang, Dongli Zhao, Qing Li, Feng-Zhan Qin, Yongqiang Zhang, Mingzhong Li, Ming C. Liau, Fang Li, Changquan Ling, Zhiqiang Meng, Yanjun Zhang, Qi-zhong Zhang, Jun Ren, Fengyi Feng
Publikováno v:
Chinese Journal of Clinical Oncology. 2:706-716
Objective The objective of this study was to explore the effect of CDA-2, a selective inhibitor of abnormal methylation enzymes in cancer cells, on the therapeutic efficacy of cytotoxic chemotherapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::743c0deff55bfc8f8774ddb16c78545c
https://doi.org/10.1007/bf02819536
https://doi.org/10.1007/bf02819536
Autor:
De Yun Luo, Yuan Kai Shi, Yiping Zhang, Wei Jing Zhang, Xiao Hui He, Yunpeng Liu, Qiang Chen, X Y Ke, Jianmin Wang, Xiao Qing Liu, Yun Zhong Zhu, Jian Hua Chang, An Lan Wang, Yang Zhang, Wei Lian Li, Xiu Wen Wang, Hua Qing Wang, Ze Fei Jiang
Publikováno v:
Anti-cancer drugs. 24(6)
The purpose of this study was to compare the efficacy and safety of a single subcutaneous injection of pegylated filgrastim with daily filgrastim as a prophylaxis for neutropenia induced by commonly used chemotherapy regimens. Fifteen centers enrolle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::459e06300885d2be871487360d3266e4
https://pubmed.ncbi.nlm.nih.gov/23571496
https://pubmed.ncbi.nlm.nih.gov/23571496
Autor:
Mei-lin, Liao, Yun-zhong, Zhu, Long-yun, Li, Huan-ying, Wan, Shi-ying, Yu, Belinda, Hall, Teena, West, Li, Wang
Publikováno v:
Chinese medical journal. 121(10)
Gemcitabine plus cisplatin is a standard treatment for stages IIIB and IV nonsmall cell lung cancer (NSCLC). This randomized phase II study evaluated a 3-week versus a 4-week schedule of gemcitabine-cisplatin as first line treatment for Chinese patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bae8d7bbaa6890ab7e3ca9a6c9c76cb6
https://pubmed.ncbi.nlm.nih.gov/18706202
https://pubmed.ncbi.nlm.nih.gov/18706202
Autor:
Chun, Huang, Kai, Li, Xi-Yin, Wei, Rui-Fang, Niu, Yan, Sun, Jin-Wan, Wang, Yun-Zhong, Zhu, Li-Yan, Xu, Xiao-Qing, Liu, Hong-Jun, Gao, Jing-Min, Zhou, Xiu-Wen, Wang
Publikováno v:
Zhonghua zhong liu za zhi [Chinese journal of oncology]. 28(10)
To investigate the changes and clinical value of circulating endothelial cells (CEC) in the peripheral blood of advanced NSCLC patient.Sixty-seven advanced NSCLC patients were randomly divided into either the treatment group with NP plus endostatin o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dce2e969809ffaab9a0013f45c86420a
https://pubmed.ncbi.nlm.nih.gov/17366796
https://pubmed.ncbi.nlm.nih.gov/17366796
Publikováno v:
Zhonghua zhong liu za zhi [Chinese journal of oncology]. 28(10)
To evaluate the efficacy and adverse events of irinotecan (CPT-11) combined with cisplatin (DDP) in the treatment of patients with advanced non-small cell lung cancer (NSCLC).Of 36 NSCLC patients consisting of 23 males and 13 females with a medium ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c2c462b798e216640e78a6c830e6eb0b
https://pubmed.ncbi.nlm.nih.gov/17366795
https://pubmed.ncbi.nlm.nih.gov/17366795
Autor:
Yuan-kai, Shi, Xiao-hui, He, Sheng, Yang, Hua-qing, Wang, Ze-fei, Jiang, Yun-zhong, Zhu, Xiao-yan, Ke, Yang, Zhang, Yun-peng, Liu, Wei-jing, Zhang, Zhao, Wang, Qing-zhi, Shi, Xiao-dong, Xie, He-long, Zhang, Jie-jun, Wang, De-yun, Luo, Qing-shan, Zheng, Rui-yuan, Sun
Publikováno v:
Zhonghua yi xue za zhi. 86(48)
To compare the efficacy and safety of daily administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF), and a single subcutaneous injection of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF), a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::56286c9c8e23e5f4f3b38f0825315c1f
https://pubmed.ncbi.nlm.nih.gov/17313855
https://pubmed.ncbi.nlm.nih.gov/17313855
Autor:
Jun-ling, Li, Xiang-ru, Zhang, Ji-wei, Liu, Zhong-yuan, Chen, Ying-cheng, Lin, Yuan-dong, Wang, Qiang, Chen, Ke-jun, Nan, Shu-ping, Song, Fu-cai, Han, Yun-zhong, Zhu, Long-yun, Li, Yu-hong, Zheng, Da-Tong, Chu
Publikováno v:
Zhonghua zhong liu za zhi [Chinese journal of oncology]. 28(4)
The purpose of this phase I/II study is to investigate the safety/toxicity profile of weekly administration of docetaxel in combination with cisplatin for the chemo-naive patients with advanced non-small cell lung cancer (NSCLC), and to evaluate the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::aed6d53dca65e915a2b52e30840f541c
https://pubmed.ncbi.nlm.nih.gov/16875636
https://pubmed.ncbi.nlm.nih.gov/16875636
Autor:
Lin, Yang, Jin-wan, Wang, Yan, Sun, Yun-zhong, Zhu, Xia-qing, Liu, Wei-lian, Li, Li-jun, Di, Pei-wen, Li, You-liang, Wang, Shu-ping, Song, Chen, Yao, Li-fen, You
Publikováno v:
Zhonghua zhong liu za zhi [Chinese journal of oncology]. 28(2)
To investigate the response rate (RR), time to tumor progression (TTP), quality of life (QOL) and adverse reaction in the treatment of pretreated advanced non-small cell lung cancer (NSCLC) using escalated doses of rh-endostatin (YH-16), and to deter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::95f007ad86854d399c45c64b2e1aca7b
https://pubmed.ncbi.nlm.nih.gov/16750022
https://pubmed.ncbi.nlm.nih.gov/16750022